Affinity-matured recombinant immunotoxin targeting gangliosides 3′-isoLM1 and 3′,6'-isoLD1 on malignant gliomas

References

• Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17:2572 - 8; PMID: 10561324
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science 1991; 252:1657 - 62; http://dx.doi.org/10.1126/science.2047874; PMID: 2047874
   PubMed Web of Science ®Google Scholar
• Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23:1137 - 46; http://dx.doi.org/10.1038/nbt1141; PMID: 16151407
   PubMed Web of Science ®Google Scholar
• Vukelić Z, Kalanj-Bognar S, Froesch M, Bîndila L, Radić B, Allen M, et al. Human gliosarcoma-associated ganglioside composition is complex and distinctive as evidenced by high-performance mass spectrometric determination and structural characterization. Glycobiology 2007; 17:504 - 15; http://dx.doi.org/10.1093/glycob/cwm012; PMID: 17293353
   PubMed Web of Science ®Google Scholar
• Liu Y, Yan S, Wondimu A, Bob D, Weiss M, Sliwinski K, et al. Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth. Oncogene 2010; 29:3297 - 306; http://dx.doi.org/10.1038/onc.2010.85; PMID: 20305696
   PubMed Web of Science ®Google Scholar
• Svennerholm L, Fredman P, Jungbjer B, Månsson JE, Rynmark BM, Boström K, et al. Large alterations in ganglioside and neutral glycosphingolipid patterns in brains from cases with infantile neuronal ceroid lipofuscinosis/polyunsaturated fatty acid lipidosis. J Neurochem 1987; 49:1772 - 83; http://dx.doi.org/10.1111/j.1471-4159.1987.tb02435.x; PMID: 3681296
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Longee DC, McLendon RE, Fuller GN, Friedman HS, Fredman P, et al. Lactotetraose series ganglioside 3′,6′-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. Cancer Res 1993; 53:120 - 6; PMID: 8416736
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Fredman P, Svennerholm L, Humphrey PA, Bigner SH, Bigner DD. Monoclonal antibodies to malignant human gliomas. Mol Chem Neuropathol 1992; 17:137 - 46; http://dx.doi.org/10.1007/BF03159988; PMID: 1384525
   PubMedGoogle Scholar
• Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs 2003; 17:155 - 67; http://dx.doi.org/10.2165/00063030-200317030-00002; PMID: 12749752
   PubMed Web of Science ®Google Scholar
• Fredman P. Gangliosides associated with primary brain tumors and their expression in cell lines established from these tumors. Prog Brain Res 1994; 101:225 - 40; http://dx.doi.org/10.1016/S0079-6123(08)61952-4; PMID: 8029453
   PubMed Web of Science ®Google Scholar
• Hedberg KM, Mahesparan R, Read TA, Tysnes BB, Thorsen F, Visted T, et al. The glioma-associated gangliosides 3′-isoLM1, GD3 and GM2 show selective area expression in human glioblastoma xenografts in nude rat brains. Neuropathol Appl Neurobiol 2001; 27:451 - 64; http://dx.doi.org/10.1046/j.1365-2990.2001.00353.x; PMID: 11903928
   PubMed Web of Science ®Google Scholar
• Fredman P, von Holst H, Collins VP, Dellheden B, Svennerholm L. Expression of gangliosides GD3 and 3′-isoLM1 in autopsy brains from patients with malignant tumors. J Neurochem 1993; 60:99 - 105; http://dx.doi.org/10.1111/j.1471-4159.1993.tb05827.x; PMID: 8417168
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, He XM, Fuller GN, Bigner SH, Fredman P, Svennerholm L, et al. Occurrence of lacto series gangliosides 3′-isoLM1 and 3′,6′-isoLD1 in human gliomas in vitro and in vivo. J Neuropathol Exp Neurol 1991; 50:756 - 69; http://dx.doi.org/10.1097/00005072-199111000-00007; PMID: 1748882
   PubMed Web of Science ®Google Scholar
• Gottfries J, Mansson JE, Fredman P, Wikstrand CJ, Friedman HS, Bigner DD, et al. Ganglioside mapping of a human medulloblastoma xenograft. Acta Neuropathol 1989; 77:283 - 8; http://dx.doi.org/10.1007/BF00687580; PMID: 2922991
   PubMed Web of Science ®Google Scholar
• Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, et al. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 1999; 5:2646 - 52; PMID: 10499644
   PubMed Web of Science ®Google Scholar
• Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, et al. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts. Clin Cancer Res 1999; 5:1539 - 49; PMID: 10389943
   PubMed Web of Science ®Google Scholar
• Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52:3402 - 8; PMID: 1596900
   PubMed Web of Science ®Google Scholar
• Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang QC, et al. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proc Natl Acad Sci U S A 1995; 92:2765 - 9; http://dx.doi.org/10.1073/pnas.92.7.2765; PMID: 7708720
   PubMed Web of Science ®Google Scholar
• Murphy K, Travers P, Walport M, Janeway C. Janeway's immunobiology. New York: Garland Science, 2012.
   Google Scholar
• Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999; 17:568 - 72; http://dx.doi.org/10.1038/9872; PMID: 10385321
   PubMed Web of Science ®Google Scholar
• Hawley TS, Hawley RG. Flow cytometry protocols. Totowa, N.J.: Humana Press, 2004.
   Google Scholar
• Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 2013; http://dx.doi.org/10.1158/1078-0432.CCR-12-3891; PMID: 23857604
   PubMed Web of Science ®Google Scholar
• Hedegaard CJ, Pegram CN, Bigner DD, Poulsen HS. Internalization of the dual-specific immunotoxin D2C7-(scdsFv)-PE38KDEL in malignant glioma cell lines [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4. Chicago, IL, Philadelphia (PA): AACR; Cancer Res, 2012; 72(8 Suppl):Abstract nr 2732.
   Google Scholar
• Kreitman RJ, Chaudhary VK, Waldmann T, Willingham MC, FitzGerald DJ, Pastan I. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. Proc Natl Acad Sci U S A 1990; 87:8291 - 5; http://dx.doi.org/10.1073/pnas.87.21.8291; PMID: 2236041
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Fredman P, Svennerholm L, Bigner DD. Detection of glioma-associated gangliosides GM2, GD2, GD3, 3′-isoLM1 3′,6′-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. Prog Brain Res 1994; 101:213 - 23; http://dx.doi.org/10.1016/S0079-6123(08)61951-2; PMID: 7518092
   PubMed Web of Science ®Google Scholar
• Molin K, Månsson JE, Fredman P, Svennerholm L. Sialosyllactotetraosylceramide, 3′-isoLM1, a ganglioside of the lactotetraose series isolated from normal human infant brain. J Neurochem 1987; 49:216 - 9; http://dx.doi.org/10.1111/j.1471-4159.1987.tb03417.x; PMID: 3585330
   PubMed Web of Science ®Google Scholar
• Pastan I, FitzGerald D. Recombinant toxins for cancer treatment. Science 1991; 254:1173 - 7; http://dx.doi.org/10.1126/science.1683495; PMID: 1683495
   PubMed Web of Science ®Google Scholar
• Allured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A 1986; 83:1320 - 4; http://dx.doi.org/10.1073/pnas.83.5.1320; PMID: 3006045
   PubMed Web of Science ®Google Scholar
• Provenzale JM, Mukundan S, Dewhirst M. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. AJR Am J Roentgenol 2005; 185:763 - 7; http://dx.doi.org/10.2214/ajr.185.3.01850763; PMID: 16120931
   PubMed Web of Science ®Google Scholar
• Buchner J, Pastan I, Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 1992; 205:263 - 70; http://dx.doi.org/10.1016/0003-2697(92)90433-8; PMID: 1332541
   PubMed Web of Science ®Google Scholar
• Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 2005; 280:607 - 17; PMID: 15491997
   PubMed Web of Science ®Google Scholar
• Kadan MJ, Sturm S, Anderson WF, Eglitis MA. Detection of receptor-specific murine leukemia virus binding to cells by immunofluorescence analysis. J Virol 1992; 66:2281 - 7; PMID: 1312632
   PubMed Web of Science ®Google Scholar
• Shapira A, Benhar I. Toxin-based therapeutic approaches. Toxins (Basel) 2010; 2:2519 - 83; http://dx.doi.org/10.3390/toxins2112519; PMID: 22069564
   PubMed Web of Science ®Google Scholar